Upgrade to SI Premium - Free Trial

BofA/Merrill Lynch Downgrades Pacira Pharmaceuticals (PCRX) to Neutral Citing Fair Valuation following Rebound

August 6, 2018 6:11 AM
BofA/Merrill Lynch downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst PT Change Downgrades

Next Articles